It’s definitely the latter, dude hates the nitty gritty of Being the Guy, he just wants everybody to admire him for Being the Guy. He’s gonna pick UFC fight on his lawn every day of the week.
Lihat kiriman asli pada platform media sosial terkait.
Hello fediferse, I was wondering, if I ever want to delete a post or an account on a service that uses ActivityPub, like Mastodon or Pixelfed, is it going to persist across the fediverse? Let’s say I made a political post on Mastodon using a profile with my real name and picture and I need to travel to the U.S. for work purposes and I don’t want the CBP to find out about it and get turned back or arrested on entry. If I delete this post, will it be completely removed across all instances that synchronized it? Is a deleted post traceable in any way? Is it kept in a log or a database on ferdiverse instances? With governments across the globe increasingly surveiling us online and scrutinizing everything we say, I’m starting to think I should plainly delete any account that has personally identifiable information like my real name and photo. I initially thought it would be easier to connect with family and friends, but now I’m growing increasingly worried about how this can be used against me. I just want to know if I can completely erase any post or any account from the fediverse or if there will always be a trace somewhere and it could get picked up by any government surveilance. Whether encrypted or not.
I am sorry, but “creating a file” may literally be anything, too, including just recording, downloading, renaming it etc. Is it possible to share the actual source of the file, and what were the circumstances you’ve got one in?
Lihat kiriman asli pada platform media sosial terkait.
Quality of life in Tibet improved enormously under Chinese rule. LIfe expectancies rose from 37 to 78. Literacy jumped from the low 30%s to the mid 70%s. Tibetan lay residents owned their own homes for the first time in their nation’s history. The region’s economy expanded rapidly as did the population, thanks to modernizations in transportation, agriculture, and health care. Meanwhile, with the colonial status of Hong Kong at an end and the city incorporated into the general Chinese economy, neighboring Shenzhen has enjoyed a similar economic boom. Residents can move freely into and out of the SEZ in a way they couldn’t under English occupation, they use a common currency rather than relying on conversions to and from British pounds, and they are free from British home rule. Most importantly, the residents are subject to the same taxation and civil rights afforded to the rest of the country - bringing an end to such labor atrocities as the 996 system, tax avoidance, and ecological crimes like illegal fishing and dumping. Given the nightmarish wave of fascist policies currently spilling over the UK, I cannot imagine why anyone would envy living on the other side of the planet while being subjected to a Tommy Robinson inspired government.
Lihat kiriman asli pada platform media sosial terkait.
Oh, good to hear someone say they enjoyed the whole series. I’ll likely add the other to my reading list (I read a pretty fair amount).
Lihat kiriman asli pada platform media sosial terkait.
Context
Beloved Party For Socialism and Liberation member and volunteer with Nuestro Barrio Liberation Center, Thomas Crowe-Allbritton, passed away on Friday morning, June 5th, 2026. A community organizer for much of his life, Thomas dedicated himself to building the PSL in North Carolina. He lived in Durham at the time of his death, where he was a much-loved member of the Triangle Branch. Born in Dothan, Alabama, Thomas moved all across the South, witnessing firsthand how, in his words, “beautiful souls are crushed” by capitalism. He spent much of his youth in Oxford, North Carolina (he would later joke about dreaming of one day moving to “the big city,” Durham). At 14 years old, Thomas was diagnosed with epithelioid hemangioendothelioma, also known as EHE, a rare form of cancer that affects the blood vessels and bone marrow. Tests revealed three tumors in his skull, two in his spine, and that the blood vessels in his lungs were covered with bean-sized tumors. In the years following, Thomas went through round after round of treatment and chemotherapy while navigating the expensive and insufficient U.S. healthcare system. He was thrown off Medicaid twice while on treatment and later stopped treatment altogether due to not being able to afford the thousands of dollars of monthly costs. Amid these immense health challenges, Thomas poured into his community and vowed to spend his life fighting for a system in which every person lives in dignity. “The diagnosis forced me to take a look at myself and see what I’m doing with my life,” he said. “I don’t know how long I have because it’s such a rare cancer. I might have it for the rest of my life and live healthy. I might die when I’m 30. It’s important that I focus on the time I have now and do as much as I can for others.” After graduating high school, Thomas studied history at UNC Pembroke. He immersed himself in campus life and student organizing, serving as the Student Government Association President and a proud member of the Eta Beta Chapter of Phi Mu Alpha Sinfonia. His time in Pembroke was heavily politicized by social justice movements, from the struggle against the Atlantic Coast Pipeline’s construction through Lumbee lands to the Black Lives Matter uprisings that led to protests and racial confrontations in Pembroke. Despite online threats from white supremacists and being flashed a gun at a BLM protest in Pembroke, Thomas never retreated from his deep convictions for justice for all working and oppressed people. Thomas at BLM Protest at Pembroke June 26th, 2020 Always with a thick book in one hand and a cup of coffee in the other, Thomas had a passion for learning and educating. After graduating from UNC Pembroke, he pursued a master’s degree in public policy at Duke. He got involved in student and community organizing through joining the Duke Graduate Student Union, interning at Democracy North Carolina, and leading Changed Paths, a mutual aid project in East Durham. Through his historical study, experience in labor organizing and mutual aid, participation in the mass movement for the liberation of Palestine, and through his personal battle with the U.S. healthcare system, Thomas formed a deep understanding that something is fundamentally wrong with the system that dominates our world and puts profit over people at every turn. Determined to change the world, Thomas joined the Party for Socialism and Liberation in November 2024. He threw himself into the party, traveling across North Carolina to support local struggles and build class consciousness. Thomas was a key organizer against the anti-immigrant bill SB-153, helping lead press conferences, protests, and outreach sessions. In Durham, Thomas helped defeat developers’ efforts to rezone Heritage Square by canvassing and delivering fiery speeches at City Council meetings. He facilitated popular education on topics from fair housing to imperialism. In Fayetteville, he supported comrades waging a fight against a dangerous curfew policy targeting Black youth. Throughout his time in the PSL, Thomas held a deep belief in the working class. He would talk to anyone and saw potential in everyone. He often cited the words of Rev. Dr. Sam Wells on the importance of being with people rather than working for them. Thomas speaking at a protest against Border Patrol Deployment to Charlotte Nov 16th, 2025 In his final months, Thomas refused to let his failing health stop him from fighting for the liberation of working people in North Carolina and across the globe. When the Trump Administration sent Border Patrol to Charlotte in November of 2025, Thomas helped lead a march at the state capitol, where he called out the Democratic Party in NC for welcoming ICE with open arms. At Nuestro Barrio Liberation Center, he coordinated screenings of the People’s Forum Hidden Histories of Rebellion course, introducing dozens of new people to an untold history of the United States. Just this past March, Thomas traveled to Wilmington, NC after the murder of 21-year-old Edilberto Espinoza-Sierra by Wilmington Police. He supported local protests, did outreach to spread the word, and connected with Edilberto’s family to uplift their story. Thomas was also a proud union organizer with the Union of Southern Service Workers. At USSW, he built deep relationships with workers at Amazon, Duke University and Hospital, and in the service and hospitality sector. It would be difficult to find a Marco’s Pizza or a Bojangles in Durham that didn’t hear Thomas’s Alabama twang asking workers, “They workin y’all to death out here!” Or his signature “how you living off only $10hr in Durham?!” Even after flare-ups would put him back in the hospital, Thomas would preach to the night-shift nurses and convince them to sign the Durham Rising petition. Everywhere Thomas went, he was a servant of the people. Whether it was handing out food, building homes with Habitat, organizing workplaces, or his vigorous research and study of history to learn how to win a society where everyone has the right to a dignified life, Thomas was a champion of humanity who inspired thousands of people across North Carolina. His example of self-sacrifice, genuineness, and devotion to learning is what we should all aspire to. Rest in peace and power to our dear comrade, Thomas Crowe-Allbritton.
Lihat kiriman asli pada platform media sosial terkait.
Bullets: Western drug companies are pouring tens of billions of dollars into China, to develop medicines that can be resold at premium prices in Europe and the United States. China dominates all phases of the pharmaceutical industry, from new drug development, testing, and mass production. Inside China / Business is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Report: Good morning. Last week the Pentagon blacklisted a group of Chinese companies, including a biotech firm, Wuxi AppTec. That means that US government contracts with Wuxi AppTec are restricted going forward. The Untied States wants to reduce its dependence on China’s pharmaceutical industry, and the Pentagon’s move is a warning to Chinese companies who want access to the $500 billion drug market in the US. The thinking is that Beijing’s dominance in biotech research and drug development will put the United States in the same spot as in for most of the world’s raw materials supply chains, and in rare earth metals and magnets. China’s restrictions on the exports of rare earths means that the Pentagon can’t build advanced weapons platforms, or even replace the missiles and radars that Iran is blowing up in the Persian Gulf, until they can get new mines and refineries online, and then learn how to make the magnets. That’s the background there. In 2025, Wuxi revenues in the American market were 32 billion RMB, which is about $4.7 billion USD. So the US is a major market for Wuxi AppTec; about two thirds of their total sales. But here is the problem on the Americans side: Wuxi helps make a fourth of the drugs and medicines used in the United States, including for the most expensive drugs. Members of Congress are drafting laws, which also target Chinese biotech firms. American drug companies like Pfizer and Bristol Myers are outsourcing research and development work and manufacturing to the Chinese companies, and the Biotech Investment National Security Act would subject those deals to the same high scrutiny they use on Nvidia, for example. Investments in biotechnology will be reviewed by the Treasury Department, and the War Department will assess whether they affect national security. These investments now are enormous, and suddenly so. Pfizer and BMY were two of dozens of companies, which combined for $136 billion worth of licensing deals with Chinese drugmakers. That is a 27 times increase in just five years. Drug companies in the United States and Europe pay Chinese labs to develop the medicines, which are then sold in Western markets with big markups. Naturally that also attracts venture capital money, and VC firms are worried that Congress may harm China’s biotech industry, which will in turn blow up the money-printing machine they’ve got going. They shouldn’t worry about that first part though: It’s already too late to stop Chinese biotech firms. Whether or not they are allowed to license drugs in the US is irrelevant, when they are building drugs for the entire world. The United States is the most lucrative pharmaceutical market, but it’s American and European drug companies who grab most of those profits, along with VC and Private Equity firms who buy up shares in the early-stage drugs. And there are lots of headlines now like this one: drugs developed in China perform better than blockbuster, high-profit drugs on the market in the US. Industry insiders know all that, and the Pentagon blacklisting won’t move the needle at all, on the partnerships between Chinese drug development companies, and the big pharma companies who put their logo on the side of the box and jack up the price a hundred times. China has no peer in building quality compounds at low cost. One issue is keeping all the executives at Western pharma companies awake at night: it’s the patent expirations problem. Morgan Stanley crunched the numbers, and Big Pharma had sales last year of $171 billion from drugs that will go off-patent over the next five years. At Pfizer, it’s an $18 billion problem by 2028, and $20 billion by 2030: (These charts are in billions, not trillions.) Pfizer is PFE, and that $20 billion is about 30% of its total sales, which will be dramatically reduced when those particular drugs go off-patent. At Bristol Myers, BMY, it’s $26 billion in sales that go away, and nearly 60% of its sales. Amgen needs to build new drugs to replace over 60% of their sales. At the moment a drug loses its patent protections, the market opens up to generics from several companies, and the price collapses, along with profit margins. Drug prices fall from 30 to over 80% on average, and the steepest declines are in the American market, because that’s where the prices are set the highest. So Keytruda is a $30 billion drug for Merck, and goes off-patent in 2028 both here and in the United States. And this is why it’s a much bigger problem for them, in the United States: In, Keytruda treatments cost $1,500 to $3,000 dollars each, with a full year cost of $20,000, at the most. In the United States, that’s the cost of a single dose. And a full year of Keytruda treatment costs $150,000 in the United States. Over seven times as much, for the same drug. And your first thought is probably something like, why don’t patients in the United States just fly to China, check into a luxury hotel right next to the hospital, get the treatment there, and fly home and save a hundred thousand dollars? If it’s obvious to us, it’s obvious to Chinese too, and we’ll come back to that. Plus, we’ve just learned that Akeso developed a drug that works better than Keytruda, anyway. Eliquis is a blood-thinner drug used to prevent clots. It comes from Bristol Myers Squibb, and last year threw off over $13 billion in sales. It loses patent protection in 2028 in the United States. In China, Eliquis costs $60 for a 30-day supply. In the US it’s anywhere from 5 to 10 times that depending on the pharmacy the patient is using. Those “patent cliffs” are a major crisis for Big Pharma, but a major opportunity for firms here. China’s biotech companies work faster, with lower costs, and so companies are paying up-front for research to be done here, as soon as possible, to get new drugs ready to sell. Neil Roberts is one of our channel’s compadres, and he’s always sniffing around the internet for stories and angles that are flying under everyone else’s radars. He doesn’t like these deals any more than our Congress does, but for a different reason. His concern is that the Chinese companies may be compromised, by spending their valuable time to develop high-profit-margin drugs for Pfizer and other companies operating in the US market, instead of doing what’s best for everyone else, everywhere else. And that’s valid. We also find it curious that Pfizer donated thousands of dollars to help those two members of Congress get elected, who are now drafting laws to prevent Pfizer from developing new drug pipelines in China. And that Pfizer donated millions of dollars to help President Trump celebrate his election party. And that Pfizer is at the same time sending Chinese labs billions of dollars to make sure they have drugs to sell after 2028. Wuxi Apptec does it all: the R&D, the drug discovery, scientist recruitment and training, and the mass-production. And so there are two points we want to emphasize here, with respect to the Chinese system: the government negotiates hard with drug companies, no matter where from, on fair pricing in exchange for access to China’s population of over a billion patients. But those low prices are even more a function of these Chinese companies’ capability to build and test the drugs, and the capacity to quickly scale up production after approval. Marco Rubio was a Senator in 2024, and reported that the US once enjoyed a comfortable lead in the highest-value research, and China’s biotech industry is now an instrument of “soft power”. The Chinese are selling low-cost drugs to the developing world, and Mr. Rubio—now Secretary of State Rubio—is alarmed. Going back to those math problems we did earlier, the cost differences between China and the United States, for the exact same treatments. Likang is a Chinese company that developed a personalized cancer vaccine. It’s in clinical trials for the FDA; it’s going through the approval process here in China. But the drug is already being offered to patients in Hainan. Very important section, right there. The cost of the treatment will run around $21,000. A similar drug from Merck or Moderna would be multiples of that. This drug may not ever be approved in the US at all, and if so, only at a very high price. So if you’re an American reading that, and maybe your doc has just told you there’s not much they can do for you, what are your options? And it’s on that question that American venture capital and drug companies should be really worried. There is a market for that drug, right now, but China is the only place anyone can get it. Hainan is the world’s largest free-trade zone and is also a giant zone for medical treatments. Over 30 hospitals, offering treatments and therapies that have not yet been approved even here on Mainland China. This will be a multi-trillion dollar industry, for Hainan Island, and for hospitals on the mainland who can offer treatments at a fraction of what hospitals in Europe, or especially in America will charge. Chinese firms developing treatments, and American patients unable to buy them, in the United States; for those patients, those Chinese hospitals are the only ones who can help. Chinese drugmakers will win, either way. Wuxi builds therapies that are in turn sold by American companies, at high profit margins, for the treatment of conditions that are money-no-object from the perspective of patients. These are terminal illnesses, and Wuxi is the only company making the treatments for some of them. Replacing Wuxi in the supply chains means there’s no more coming for years, and remember, American drug companies don’t have “years”. A third of their revenues are going away, starting next year. So the money is pouring in to China to develop new drugs, and soon enough the money will be pouring into China by patients who need treatments that are not even approved in their home countries, or who do the math and figure that it’s like being paid a hundred thousand dollars to take a vacation in Hainan and receive treatment there. This is another company, Hengrui, who is now the top clinical sponsor in the world, with over 400 ongoing clinical trials, and multi-billion-dollar deals with Merck and Glaxo Smith Kline. This did all happen very fast. Just like in everything else, no matter how much our political leadership likes to pretend otherwise. True experts and industry insiders know it. “There is no sense that these are areas the US can win”. Precision medicine, biotech, and medical equipment are literally national-level priorities, national security priorities, for the Chinese government. And while that kind of emphasis would drive prices and costs way up in the American market, like we see at the Pentagon, for example, in China the cost structures go the other way. The system is more efficient, so costs fall, and timelines speed up. Since 2021—and that five-year plan—the number of drugs under development increased eight times. China is committed to excellence in service, and the US is not stepping up and competing, and cannot. Morgan Stanley again, and drugs coming from China will grow to $34 billion in five years, and $220 billion in fifteen years, and a major driver of that increase is that the treatments are for the high-profit-margin drugs. China is investing in the R&D, and in the people and facilities. Zhangjiang Gaoke is in Shanghai, and home to over 1700 medical companies in a single zone. Seed capital investment in US biotech is at the lowest level in over 20 years, so it’s only the Chinese companies now who are doing the hard work of drug research and discovery. Much of that work is very labor-intensive, by highly skilled chemists. So, it’s cost-prohibitive to even try it in San Francisco or Boston. Pudong, Shanghai isn’t cheap, either, but China is where the people are, and those Chinese PhD’s are building the highest-value drugs. China built a new system, while the industry in the United States headed the opposite way. China approved 20,000 new drugs in just two years; in the same time it takes the FDA to look at three hundred or so. And so Chinese companies, and some American ones, are indifferent as to what the Pentagon or Congress does. China is that blue parabola that now is the world leader in new drug discovery and development for the most valuable drugs: China is also that blue line, for Clinical Trial Activity: China is doing more trials than the United States and the EU combined, and there’s a big reason why: Phase I trials take two years in the US but get done in about a third that time in China. In other words, China is doing more trials, and finishing them faster. Here’s another blue line: license-out deals, which tripled from 2024 to 2025. Last year worth $135 billion: And this year, 2026, it’s growing even faster. In the first three months, $60 billion, which is two times the rate of 2025, and 2025 was 10 times bigger than 2021. So that’s the concern on the US side: Western companies are addicted to the low-cost drugs coming out of China, which they can mark up to American patients for hundreds of billions of dollars. But it’s also causing some problems here, for Chinese policymakers, who are concerned in the same way Neil Roberts was in his email to us. The first priority for Chinese drugmakers, should be to care for Chinese patients. Regulators understand that some of these most novel and revolutionary treatments fall far outside the traditional processes for testing and approval. Personalized medicine – precision medicine – is completely different, and millions of patients are suffering, right now. Those patients need faster approvals for those therapies, and they also need companies who will build them. Anew regulatory pathway for treatments for rare and terminal-stage diseases is being established. The objective, specifically, is improved access to the most advanced therapies for Chinese patients. Those new protocols will offer vast new revenue opportunities for Chinese biotech firms, while reducing their need to partner with the Pfizer’s and the Merck’s of the world just to keep the lights on and their people paid. There is massive demand, right now: patients who need new drugs, and need Chinese companies specifically to build them. That new industry will be all-China: all the drug development, and all the treatment, first to Chinese patients, and then to anyone else who buys a plane ticket to Hainan. Be Good. Resources and links: Pentagon casts dark cloud over China biotech https://www.reuters.com/commentary/breakingviews/pentagon-casts-dark-cloud-over-china-biotech-2026-06-09/ Moolenaar, Dingell Introduce Legislation to Prevent Offshoring Biotech Industry to China https://chinaselectcommittee.house.gov/media/press-releases/moolenaar-dingell-introduce-legislation-to-prevent-offshoring-biotech-industry-to-china House bill aims to crack down on China biotech deals https://www.biopharmadive.com/news/binsa-china-biotech-deals-house-moolenaar-dingell/821841/ China’s Biotech Is Cheaper and Faster https://www.nytimes.com/2025/08/17/opinion/china-biotech.html Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs https://www.nytimes.com/2024/04/15/health/wuxi-us-drugs-congress.html China’s biotech industry sees global expansion as unstoppable, despite US pressure https://www.scmp.com/business/china-business/article/3356778/chinas-biotech-industry-sees-global-expansion-unstoppable-despite-us-pressure Chinese drugmaker becomes top trial sponsor — and other clinical trends https://www.pharmavoice.com/news/chinese-china-drug-clinical-trial-pharma-jiangsu-hengrui/804665/ US drug pricing policies are ‘red lights’ for investors, and China beckons https://www.pharmavoice.com/news/drug-pricing-red-lights-biopharma-china-venture-capital/810167 China turns the tables in biotech https://www.science.org/doi/10.1126/science.aef7757 Patent cliffhanger: will China biotech throw Big Pharma a lifeline? https://www.scmp.com/business/china-business/article/3337038/patent-cliffhanger-will-china-biotech-throw-big-pharma-lifeline Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts https://www.scmp.com/business/china-business/article/3356564/chinese-pharmaceutical-firms-cost-advantages-trump-pentagon-blacklist-analysts The paradox of biotech protectionism: Why walling off China biotech weakens America https://rapport.racap.com/all-stories/the-paradox-of-biotech-protectionism-why-walling-off-china-biotech-weakens-america The Innovation Boom in China Biotech https://www.morganstanley.com/insights/articles/china-biotech-boom-generics-to-innovators How China Became the Biotech Industry’s Back-Office https://www.forbes.com/sites/shimiteobialo/2026/01/21/how-china-became-the-biotech-industrys-back-office/ As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too https://www.fiercebiotech.com/biotech/divisive-bill-seeks-add-biotech-industry-law-limiting-investment-chinese-industry The Year China Surpassed the USA in Biotech Innovation, Deal Value, and Clinical Output https://www.synbiobeta.com/read/the-year-china-surpassed-the-usa-in-biotech-innovation-deal-value-and-clinical-output The China question is tearing biotech apart https://www.statnews.com/2026/05/18/biotech-industry-split-chinese-drugs-opportunity-versus-existential-threat/ Amid a flurry of biotech deals, China looks to keep innovation at home https://www.pharmavoice.com/news/licensing-pharma-deal-china-regulation-policy/822443/ Political contributions data from OpenSecrets.org US says BYD, Baidu, Alibaba and other tech giants are aiding China’s military https://www.reuters.com/world/asia-pacific/pentagon-lists-entities-designated-chinese-military-company-2026-06-08/ On this Chinese island, patients are trying latest experimental drugs for cancer https://www.scmp.com/news/china/science/article/3310623/chinese-island-patients-are-trying-latest-experimental-drugs-cancer Inside China / Business is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. From Inside China / Business via This RSS Feed.
The remake of the creaky 25-year-old RPG has already hit 500k sales.
Comments
Lihat kiriman asli pada platform media sosial terkait.
Iranian sources claim a sophisticated intelligence operation tracked US P-8 aircraft and F-35 jets across multiple bases in the Gulf and Jordan. Iran has executed a sophisticated intelligence and operational plan in the strikes launched against several US military bases in the region early Thursday morning, Fars reported, citing a senior Iranian military source. The source, speaking to Fars News Agency, stated that the strikes inflicted significant losses on expensive equipment belonging to US forces in the region. In a detailed account of the operation, the source reported that Iranian forces tracked the flight path and positioning of two large US P-8 aircraft from the moment they took off. One of the aircraft was reportedly arriving from the Diego Garcia airbase in the central Indian Ocean, while the other was flying from a US base in Western Europe, heading toward the southern Gulf. According to the source, the precise locations of these two aircraft, at the Shaikh Isa Air Base in Bahrain and the Ali Al Salem Air Base in Kuwait, were subsequently struck by Iranian precision weapons. Furthermore, Iran monitored the positioning of at least three US F-35 fighter jets inside a hangar at the Muwaffaq Salti Air Base in Jordan. The source asserted that the surveillance continued until the final moments before missile launches, at which point the exact location of the hangar was targeted with long-range, solid-fuel missiles. Iran retaliates to US aggression, hits US basesEarlier on Thursday, Iran’s Islamic Revolution Guard Corps (IRGC) announced it launched retaliatory strikes against US military positions in Jordan, Kuwait, and Bahrain, in a “punitive action against the aggressor” operation in response to renewed US aggression against Tehran. According to Tasnim News Agency, the IRGC fired 12 ballistic missiles at Jordan’s Al-Azraq Air Base and its control center, destroying what it claimed were “these facilities and a large number of fighter aircraft,” including US F-35, F-15, and F-16 jets reportedly stationed at the base. In a separate statement cited by IRNA, the IRGC said it carried out two waves of operations, striking “18 important targets belonging to the US Army” at bases in Kuwait and Bahrain. The Guard specifically identified Kuwait’s Ali Al Salem and Ahmad Al-Jaber air bases and Bahrain’s Sheikh Isa Air Base. Earlier, Iranian media reports had also indicated that the US Fifth Fleet in Bahrain came under attack. Strait of Hormuz shut downIn further retaliatory actions, the IRGC’s Khatam al-Anbiya Central Headquarters issued a statement declaring the immediate closure of the Strait of Hormuz. “From this moment, due to insecurity in the region, the Strait of Hormuz is declared closed to the passage of any type of vessel, including oil tankers and commercial ships, and any passage will be struck,” the statement said. The announcement cited “the continued mischief of criminal America” and “the beginning of attacks by that country’s aggressive army on some areas in the south of Hormozgan province.” The IRGC also denied US claims that ships were still passing through the strait, stating, “The US claim of a ship crossing the said strait is denied.” US launches aggression on IranEarlier on June 11, Iranian air defenses were activated in several areas early Wednesday after reports emerged of explosions in southern Iran and neighboring Iraq, according to Iranian state media. Air defense systems were triggered west of the capital, Tehran, while explosions were heard in the cities of Sirik and Minab, both located in the Hormozgan province. Iranian state television later reported that air defenses had also been activated in Asaluyeh, a major energy hub in southern Iran. The broadcaster added that five hostile projectiles had targeted a location in Minab. Further explosions were reported in Bandar Abbas, including in the vicinity of the city’s airport and an Air Force base, according to the official IRNA news agency. The activation of air defense systems came shortly after Iranian authorities announced heightened readiness in western Tehran and several southern regions, including strategic energy sites, as regional military tensions continue to rise. Meanwhile, Tasnim News Agency denied earlier claims of explosions on Qeshm Island and other nearby islands. The agency suggested that some of the reported sounds were linked to broader clashes in the Gulf rather than direct strikes on the islands themselves. (Al Mayadeen) From Orinoco Tribune via This RSS Feed.
No it’s fine, I just reposted it with a cw, sorry for keeping you up. Goodnight!
Lihat kiriman asli pada platform media sosial terkait.
I used to suffer from similar joint pain in my fingers that would be relieved if I popped them. It’s a lot better after going on a low inflammation diet, may be worth a try.
Lihat kiriman asli pada platform media sosial terkait.
I loved the series. Semiosis did take a bit to get started, but it had to set the stage. It really was a good book, once it got started, and the story continues into Interference and Usurpation. And, while it does “end”, I want more.
Lihat kiriman asli pada platform media sosial terkait.
A gargoyle isn’t real though Oh. Now I’m sad.
Lihat kiriman asli pada platform media sosial terkait.
People triage if this or that global south country is a dictatorship or not, while the populace in those places can actual affect policies. In the west the governments are basically untouchable and just do whatever they like, only falling from internal factions.
Lihat kiriman asli pada platform media sosial terkait.
So it’s on this polemic stuff right? So I wanted to ask for some alternatives for both the VPN and email. Any other recomendations are also welcome! And I do understand I might need to start paying for a service. Thanks a lot! Also, the only thing I don’t know much about is me using rethink dns it seems safe ig, but yea, also uhh. I also use proton through wireguard so ideally it should include that or openvpn or just really good compatibility for all devices.
Critique is good, it’s how a movement progresses. If a movement (org, party, etc) did the same thing over and over again regardless of outcome, they would eventually run in circles and into their own exhaustion. The problem is that no advancements have ever been made by a westerner saying for the nth time that china is not socialist because Y reason. To make any material change, they would have to be Chinese, they would have to be in the CPC, and they would have to bring it up there. Saying it to an English-speaking audience on Youtube, no matter how big, is just not going to change China’s mind. It is however going to change a lot of new leftists’ minds. There is the same contradiction when I yell that the US is starting yet another war on false premises, making people believe that their war is just when they have fabricated all of the justifications. But – the difference is that I yell this to people to whom it will matter. I can plant the seeds of anti-imperialism theory in people’s minds, even if they are not receptive at first. I’m not saying either are very effective in the grand scheme of things, rather I’m saying that despite similarities in tactics, both exist for different reasons. So what is their goal then? We come to the conclusion that they want to promote the idea that there is no socialism, and might never have been (some ultras believe there has never been socialism, some believe only the USSR until Stalin’s death was ever an example of socialism). I find that conclusion not only very bleak but also very dangerous. Why do people want me to believe socialism has never succeeded, and that the only attempts at socialism that have been realized in the world were bound to fail, and not actual examples of socialism? Isn’t that very defeatist? Like, what is the material reason there hasn’t been a Bordigist revolution that even grasped state power for a moment? Why is it only “fake” socialism that seems to succeed, according to ultras, and then turns into state capitalism? They are basically saying that capitalism is inescapable and there will never be anything else, but in other words from liberals. I really don’t see how you can make a career out of saying “there has never actually been socialism” and then can claim you are anything but an anti-communist mouthpiece. As for Trotskyists they are “communists who are afraid to call themselves communists”. I don’t really mean it as a compliment… I found that trots can rarely explain how their theory actually differs from what the USSR under Stalin did. They like to imagine alternative history where Trotsky “won” the “power struggle” (as if Lenin decided his successor and not the central committee of the CPSU) and how different it would have been from Stalin, when, if you read both, you realize Trotsky would probably have passed the same policies as Stalin but been even harsher than Stalin was. They think the purges are bad because anything that paints Stalin in a bad light is good to Trotskyists, but Trotsky was fond of collective punishments and particularly execution. Nobody could stand him. Frankly it’s a good thing he never ruled anything after the red army. They can’t even define permanent revolution, just that it’s “different” from socialism in one country so it’s automatically better. They can’t define socialism in one country either. In reality permanent revolution would have destroyed the fledgling USSR. They are a group that has not read anything beyong Marx, Lenin and Trotsky (presumably because anyone after Trotsky was not Trotskyist enough) and it shows. Truth is Trotsky was hated by everyone in the CPSU by the time he was first exiled to the Kazakh SSR, as he wanted to split the party and was impossible to work with. Then he tried to organize a coup. There was a reason he wasn’t elected to be general secretary.
Lihat kiriman asli pada platform media sosial terkait.